An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

Kaur, Jasneet; Kaur, Sukhmeet; Ȧnand, Amit; Islam, Nasarul; Singh, Simrandeep; Singh, Akshdeep

doi:10.1002/slct.202302778

Cited by 6 publications

(2 citation statements)

References 82 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous anticancer agents like alkylating nitrogen mustard molecules, which damage DNA by forming an irreversible covalent bond with the alkyl groups, such as cyclophosphamide and chlorambucil, and antimetabolites, which inhibit DNA synthesis by inhibiting the use of purine metabolites inside the body, such as fluorouracil and mercaptopurine, were employed to treat several forms of cancer. However, they were highly hazardous [3]. Heterocyclic compounds containing nitrogen atoms, such as quinoxaline, phthalazine, and quinazoline, have long been known for their versatile medicinal properties.…”

Section: Introductionmentioning

confidence: 99%

Quinazoline Derivatives as Targeted Chemotherapeutic Agents

Zayed

2024

Cureus

View full text Add to dashboard Cite

Most of the current chemotherapeutic medications are extremely toxic, exhibit little selectivity, and contribute to the emergence of treatment resistance. Consequently, the discovery of targeted chemotherapy drugs with high selectivity and low side effects is necessary for cancer treatment. The quinazoline system has a broad range and a long history of biological activities. Numerous quinazoline derivatives have been used to treat different types of cancer by working on various molecular targets. This review presents various chemical information, including molecular structure, design, and biological activity of some reported quinazolines that function by inhibiting four types of important molecular targets: dihydrofolate reductase, breast cancer resistant protein, poly-(ADP-ribose)-polymerase, and tubulin polymerization.

show abstract

Section: Introductionmentioning

confidence: 99%

Quinazoline Derivatives as Targeted Chemotherapeutic Agents

Zayed

2024

Cureus

View full text Add to dashboard Cite

show abstract

“…It can be classified based on its onset as either infantile esotropia, which occurs within the first 6 months of life, and acquired esotropia, which occurs after this period. 1 Acquired esotropia had been initially classified as accommodative and non-accommodative types. 2,3 Burain and Miller 4 further subdivided acute acquired non-accommodative esotropia (AACE) into Swan type, Burian-Franceschetti type, and Bielschowsky type.…”

Section: Introductionmentioning

confidence: 99%

Neuroimaging Findings in Acquired Esotropia Patients at Siriraj Hospital from 2009–2020

Surachatkumtonekul,

Khiewwan,

Hokierti

et al. 2023

Siriraj Med J

View full text Add to dashboard Cite

Objective: To analyze the neuroimaging findings in patients with acquired esotropia at Siriraj Hospital from 2009 to 2020. Materials and Methods: A retrospective review of the medical records of all patients aged above 6 months old who presented with acquired esotropia was done. All the patients had an angle of deviation 10 prism diopters (PD), refraction < +3.0 diopters (D), and had neuroimaging performed. The patients with restrictive myopathy and extraocular neurological abnormalities were excluded from the study. Results: In total, 177 subjects aged between 8 months old to 81 years old (mean age 32.35 ± 24.40 years old) were included in the study. The patients’ demographic data, ocular findings, and neuroimaging findings were collected. The mean angle of deviation near and at distance were 26.88 ± 18.90 PD and 29.81 ± 17.25 PD, respectively. Of the 177 cases, 113 cases (63.8%) had no neuroimaging abnormalities, while 64 cases (36.2%) had abnormal neuroimaging findings. In those 64 cases with abnormal findings, there were 16 intracranial tumors, 6 inflammations, 4 vascular lesions, 7 degenerations, and 31 other lesions. Sixth nerve palsy was found to be significantly different between the positive and negative neuroimaging group from both the uni- and multivariate analysis. Conclusion: Although more than half of acquired esotropia patients had no abnormalities in neuroimaging, but 14.7% of those with abnormal neuroimaging findings had underlying serious conditions, which consisted of intracranial tumors, inflammation, and vascular lesions. Special attention should be concentrated to patients with sixth nerve palsy as it was the significant factor found to be associated with positive neuroimaging findings in acquired esotropia.

show abstract

Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration

Kaur,

Muskan

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Quinazolinone derivatives have garnered attention for their diverse biological activities, including anticancer properties. This review combines findings from 2018 to 2024, focusing on the impact of quinazolinones on cancer cells, tubulin formation, and EGFR/PI3 K pathways. By unraveling the intricacies of structure‐activity relationships, this review endeavors to provide guidance for researchers in identifying promising avenues for the development of cancer treatments. Although in vitro studies underscore significant potential, it is imperative that future research prioritizes pre‐clinical investigations to seamlessly traverse the transitional phase towards clinical applications, thereby propelling the advancement of quinazolinone‐based cancer therapy.

show abstract

An Updated Overview on the Synthesis and Anticancer Evaluation of Quinazoline Derivatives

Cited by 6 publications

References 82 publications

Quinazoline Derivatives as Targeted Chemotherapeutic Agents

Quinazoline Derivatives as Targeted Chemotherapeutic Agents

Neuroimaging Findings in Acquired Esotropia Patients at Siriraj Hospital from 2009–2020

Unveiling the Therapeutic Potential of Quinazolinone Derivatives in Cancer Treatment: A Comprehensive Exploration

Contact Info

Product

Resources

About